期刊
ONCOTARGET
卷 8, 期 24, 页码 38264-38275出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.16123
关键词
androgen receptor; lipid degradation; metabolism; ECI2; cell cycle
资金
- Norwegian Cancer Society
- Norwegian Research Council
- Helse Sor-Ost
- University of Oslo through the Centre for Molecular Medicine (Norway), Nordic EMBL (European Molecular Biology Laboratory) partnership
- National Cancer Institute Cancer Center Support Grant from the National Cancer Institute Cancer Center Support Grant [CA77739, CA016056]
- NIH-NCI [CA166440]
- FASTMAN Centre, Movember Prostate Cancer Centre of Excellence [CE013_2-004]
Prostate cancer is the most common male cancer and androgen receptor (AR) is the major driver of the disease. Here we show that Enoyl-CoA delta isomerase 2 (ECI2) is a novel AR-target that promotes prostate cancer cell survival. Increased ECI2 expression predicts mortality in prostate cancer patients (p = 0.0086). ECI2 encodes for an enzyme involved in lipid metabolism, and we use multiple metabolite profiling platforms and RNA-seq to show that inhibition of ECI2 expression leads to decreased glucose utilization, accumulation of fatty acids and down-regulation of cell cycle related genes. In normal cells, decrease in fatty acid degradation is compensated by increased consumption of glucose, and here we demonstrate that prostate cancer cells are not able to respond to decreased fatty acid degradation. Instead, prostate cancer cells activate incomplete autophagy, which is followed by activation of the cell death response. Finally, we identified a clinically approved compound, perhexiline, which inhibits fatty acid degradation, and replicates the major findings for ECI2 knockdown. This work shows that prostate cancer cells require lipid degradation for survival and identifies a small molecule inhibitor with therapeutic potential.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据